A new blood test for liver scarring or fibrosis, a leading indicator of chronic liver disease, can deliver results within an hour.
The Enhanced Liver Fibrosis (ELF) test from Siemens Healthcare Diagnostics is the first automated, standardised blood test for liver fibrosis, offering clinicians a quick and reliable option.
The new test has gained CE Mark approval for use on the Siemens ADVIA Centaur Immunoassay Systems.
Siemens is the only company to offer an integrated portfolio of diagnostic solutions for managing liver health.
The ELF test combines three direct serum biomarkers in a single ELF score, which correlates to the level of liver fibrosis assessed by biopsy. A 7-year study involving over 450 patients has shown that the ELF markers are comparable to liver histology at predicting clinical outcomes of CLD.
Liver fibrosis represents the liver’s response to injury or disease. Chronic liver diseases such as cirrhosis and liver cancer are among the top 10 causes of death worldwide.
“The discovery of the ELF markers represents a significant advance in the diagnosis of patients with liver disease,” stated William Rosenberg, Joint Director of the Centre for Hepatology, University College London. “Of particular benefit, the ELF test can help to identify patients with mild-to-moderate liver fibrosis, which is usually asymptomatic, so that clinicians are able to intervene before significant damage to the liver occurs.”
Dave Hickey, CEO of Chemistry, Immunoassay, Automation and Diagnostics IT at Siemens Healthcare Diagnostics, explained that liver biopsy can cause patient discomfort and take time to interpret. “By offering an automated, routine, minimally-invasive blood test,” he said, “Siemens provides an additional tool to physicians to aid them to easily assess the severity of liver fibrosis in their patients with chronic liver disease.”
Siemens ELF test